This includes the company’s lead pre-clinical ADC candidate IKS03, a potentially ‘best-in-class’ CD19-targeted asset for B-cell cancers.
Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase I clinical trials, and will also be used to fast-track its earlier-stage programmes.
Currently, the company’s drug development pipeline is focused on the improved safety and efficacy conferred by tumour activated, prodrug payloads in combination with stable conjugation technologies.
